b'<style type="text/css">\r\n\t\t\t.cs2E86D3A6{text-align:center;text-indent:0pt;margin:0pt 0pt 0pt 0pt}\r\n\t\t\t.cs5925EB86{color:#000000;background-color:transparent;font-family:\'Century Schoolbook\';font-size:10pt;font-weight:bold;font-style:normal;}\r\n\t\t\t.cs95E872D0{text-align:left;text-indent:0pt;margin:0pt 0pt 0pt 0pt}\r\n\t\t\t.csDD5E5F52{color:#000000;background-color:transparent;font-family:\'Century Schoolbook\';font-size:10pt;font-weight:normal;font-style:normal;}\r\n\t\t\t.csED7826F6{color:#000000;background-color:transparent;font-family:\'Century Schoolbook\';font-size:14pt;font-weight:bold;font-style:italic;}\r\n\t\t\t.csE0B838BE{text-align:justify;text-indent:-86pt;margin:0pt 0pt 0pt 86pt}\r\n\t\t\t.csA16174BA{color:#000000;background-color:transparent;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;}\r\n\t\t\t.cs9224F58F{text-align:justify;text-indent:0pt;margin:0pt 0pt 0pt 0pt;line-height:12pt;mso-line-height-rule:exactly}\r\n\t\t\t.csC970676{text-align:left;text-indent:0pt;margin:0pt 0pt 0pt 0pt;line-height:12pt;mso-line-height-rule:exactly}\r\n\t\t\t.cs5ADD8C59{color:#000000;background-color:transparent;font-family:\'Century Schoolbook\';font-size:9pt;font-weight:normal;font-style:normal;}\r\n\t\t\t.csE2DB38B2{color:#000000;background-color:transparent;font-family:\'Century Schoolbook\';font-size:9pt;font-weight:bold;font-style:italic;}\r\n\t\t\t.cs5D3E032C{color:#000000;background-color:transparent;font-family:\'Century Schoolbook\';font-size:9pt;font-weight:normal;font-style:normal;text-decoration: line-through;}\r\n\t\t\t.cs41ED3027{text-align:center;text-indent:0pt;margin:0pt 0pt 0pt 0pt;line-height:12pt;mso-line-height-rule:exactly}\r\n\t\t\t.csE3E0FE0B{color:#000000;background-color:transparent;font-family:\'Century Schoolbook\';font-size:10pt;font-weight:normal;font-style:italic;}\r\n\t\t\t.cs5CA3ADAD{text-align:left;text-indent:0pt;margin:0pt 0pt 0pt 54pt;line-height:12pt;mso-line-height-rule:exactly}\r\n\t\t\t.csD15247B9{text-align:left;text-indent:0pt;margin:0pt 0pt 0pt 0pt;line-height:1.5}\r\n\t\t\t.csF0A1D375{text-align:justify;text-indent:0pt;margin:0pt 0pt 0pt 0pt;line-height:1.5}\r\n\t\t\t.cs22FF6315{color:#000000;background-color:transparent;font-family:\'Century Schoolbook\';font-size:10pt;font-weight:bold;font-style:italic;}\r\n\t\t\t.cs98AF35F2{color:#000000;background-color:transparent;font-family:\'Century Schoolbook\';font-size:10pt;font-weight:normal;font-style:normal;text-decoration: line-through;}\r\n\t\t</style>\n<!DOCTYPE html PUBLIC "-//W3C//DTD XHTML 1.0 Transitional//EN" "http://www.w3.org/TR/xhtml1/DTD/xhtml1-transitional.dtd">\r\n\r\n\t\t<p class="cs2E86D3A6"><span class="cs5925EB86">SB 284 - VERSION ADOPTED BY BOTH BODIES</span></p><p class="cs2E86D3A6"><span class="cs5925EB86">&nbsp;</span></p><p class="cs95E872D0"><span class="csDD5E5F52">&nbsp;</span></p><p class="cs2E86D3A6"><span class="csDD5E5F52">2022 SESSION</span></p><p class="cs95E872D0" style="tab-stops:left 396pt;"><span class="csDD5E5F52">\t22-2906</span></p><p class="cs95E872D0" style="tab-stops:left 396pt;"><span class="csDD5E5F52">\t11/05</span></p><p class="cs95E872D0"><span class="csDD5E5F52">&nbsp;</span></p><p class="cs95E872D0" style="tab-stops:left 108pt;"><span class="csDD5E5F52">SENATE BILL\t</span><span class="csED7826F6">284</span></p><p class="cs95E872D0"><span class="csDD5E5F52">&nbsp;</span></p><p class="csE0B838BE"><span class="csDD5E5F52">AN ACT\t</span><a name="bkTitleDraft0"><span class="csDD5E5F52">relative to the treatment of glaucoma.</span></a></p><p class="cs95E872D0"><span class="csDD5E5F52">&nbsp;</span></p><p class="csE0B838BE" style="tab-stops:left 86.45pt;"><span class="csDD5E5F52">SPONSORS:\tSen. Ward, Dist 8; Sen. Soucy, Dist 18; Sen. Watters, Dist 4; Sen. Ricciardi, Dist 9; Sen. Hennessey, Dist 1; Sen. Avard, Dist 12; Sen. Giuda, Dist 2; Sen. Birdsell, Dist 19; Sen. Whitley, Dist 15; Sen. Carson, Dist 14; Sen. Cavanaugh, Dist 16; Sen. Prentiss, Dist 5; Rep. Lundgren, Rock. 5; Rep. Yakubovich, Merr. 24</span></p><p class="cs95E872D0"><span class="csDD5E5F52">&nbsp;</span></p><p class="csE0B838BE" style="tab-stops:left 86.45pt;"><span class="csDD5E5F52">COMMITTEE:\tHealth and Human Services</span></p><p class="cs95E872D0" style="tab-stops:left 90pt;"><span class="csDD5E5F52">&nbsp;</span></p><p class="cs95E872D0" style="tab-stops:left 90pt;"><span class="csA16174BA">-----------------------------------------------------------------</span></p><p class="cs95E872D0" style="tab-stops:left 90pt;"><span class="csDD5E5F52">&nbsp;</span></p><p class="cs2E86D3A6"><span class="csDD5E5F52">ANALYSIS</span></p><p class="cs95E872D0"><span class="csDD5E5F52">&nbsp;</span></p><p class="cs9224F58F" style="tab-stops:left 18pt left 86.45pt;"><span class="csDD5E5F52">\tThis bill modifies the requirements for optometrists who treat glaucoma.</span></p><p class="cs95E872D0"><span class="csDD5E5F52">&nbsp;</span></p><p class="cs95E872D0"><span class="csDD5E5F52">- - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - </span></p><p class="cs95E872D0"><span class="csDD5E5F52">&nbsp;</span></p><p class="csC970676" style="tab-stops:left 14.4pt left 82.8pt;"><span class="cs5ADD8C59">Explanation:\tMatter added to current law appears in </span><span class="csE2DB38B2">bold italics.</span></p><p class="csC970676" style="tab-stops:left 14.4pt left 82.8pt;"><span class="cs5ADD8C59">\t\tMatter removed from current law appears [</span><span class="cs5D3E032C">in brackets and struckthrough.</span><span class="cs5ADD8C59">]</span></p><p class="csC970676" style="tab-stops:left 14.4pt left 82.8pt;"><span class="cs5ADD8C59">\t\tMatter which is either (a) all new or (b) repealed and reenacted appears in regular type.</span></p><p class="csC970676" style="tab-stops:left 396pt;"><span class="csDD5E5F52">\t22-2906</span></p><p class="csC970676" style="tab-stops:left 396pt;"><span class="csDD5E5F52">\t11/05</span></p><p class="cs95E872D0"><span class="csDD5E5F52">&nbsp;</span></p><p class="cs41ED3027" style="tab-stops:left 396pt;"><span class="csDD5E5F52">STATE OF NEW HAMPSHIRE</span></p><p class="cs41ED3027" style="tab-stops:left 396pt;"><span class="csDD5E5F52">&nbsp;</span></p><p class="cs41ED3027" style="tab-stops:left 396pt;"><span class="csE3E0FE0B">In the Year of Our Lord Two Thousand Twenty Two</span></p><p class="csC970676" style="tab-stops:left 396pt;"><span class="csDD5E5F52">&nbsp;</span></p><p class="csE0B838BE"><span class="csDD5E5F52">AN ACT\t</span><a name="bkTitleDraft1"><span class="csDD5E5F52">relative to the treatment of glaucoma.</span></a></p><p class="cs5CA3ADAD" style="tab-stops:left 396pt;"><span class="csDD5E5F52">&nbsp;</span></p><p class="cs41ED3027" style="tab-stops:left 396pt;"><span class="csE3E0FE0B">Be it Enacted by the Senate and House of Representatives in General Court convened:</span></p><p class="csD15247B9"><span class="csDD5E5F52">&nbsp;</span></p><p class="csF0A1D375" style="tab-stops:left 18pt left 36pt left 54pt left 72pt left 90pt;"><span class="csDD5E5F52">\t</span><a name="Chapt1"></a><span class="csDD5E5F52">1 &nbsp;Treatment of Glaucoma. &nbsp;Amend RSA 327:6-c to read as follows:</span></p><p class="csF0A1D375" style="tab-stops:left 18pt left 36pt left 54pt left 72pt left 90pt;"><span class="csDD5E5F52">\t327:6-c  Treatment of Glaucoma. </span></p><p class="csF0A1D375" style="tab-stops:left 18pt left 36pt left 54pt left 72pt left 90pt;"><span class="csDD5E5F52">\t\tI.(a) &nbsp;Optometrists seeking authorization to treat glaucoma shall complete at least 40 hours of classroom education, approved by the board, incorporating: &nbsp;epidemiology of the glaucomas; genetics of the glaucomas; anatomy, physiology, and mechanics of aqueous inflow and aqueous outflow; optic nerve anatomy and pathophysiology; neurotoxicity and neuroprotectants; receptor biology; pharmacology, clinical use and toxic effects of alpha and beta adrenergic agents, carbonic anhydrase inhibitors, prostanoids and cholinergic agents. </span></p><p class="csF0A1D375" style="tab-stops:left 18pt left 36pt left 54pt left 72pt left 90pt;"><span class="csDD5E5F52">\t\t\t(b) &nbsp;Optometrists shall pass an examination approved by the board that covers the educational components listed in subparagraph (a). &nbsp;Upon passage of such exam, an optometrist shall have prescriptive authority during the clinical management period pursuant to RSA 327:6-a. </span></p><p class="csF0A1D375" style="tab-stops:left 18pt left 36pt left 54pt left 72pt left 90pt;"><span class="csDD5E5F52">\t\t\t(c) &nbsp;The board shall waive the requirements of this paragraph and of paragraph II for optometrists who have either graduated after 2002 or who have proof of 12 months of credentialed privileges to treat glaucoma by the United States Department of Defense or Department of Veteran Affairs or the national Indian Health Service, </span><span class="cs22FF6315">or who are certified by the American Board of Optometry, </span><span class="csDD5E5F52">verified by the board. </span></p><p class="csF0A1D375" style="tab-stops:left 18pt left 36pt left 54pt left 72pt left 90pt;"><span class="csDD5E5F52">\t\tII.(a) &nbsp;To be authorized to initiate treatment of glaucoma for patients 18 years of age or older, a therapeutic pharmaceutical agent certified optometrist shall complete the educational requirements in paragraph I and provide evidence of written referrals and consultations with an ophthalmologist. &nbsp;For purposes of this section, [</span><span class="cs98AF35F2">&quot;glaucoma&quot; means primary open-angle glaucoma; and</span><span class="csDD5E5F52">] &quot;ophthalmologist&quot;; means a physician licensed under RSA 329 with a specialty in ophthalmology. &nbsp;The joint credentialing committee shall review evidence of glaucoma co-management submitted pursuant to subparagraph (b). </span></p><p class="csF0A1D375" style="tab-stops:left 18pt left 36pt left 54pt left 72pt left 90pt;"><span class="csDD5E5F52">\t\t\t(b) &nbsp;Except as provided in subparagraph I(c) or paragraph III, therapeutic pharmaceutical agent certified optometrists are required to provide evidence of successful collaborative treatment and co-management of 25 glaucoma patients, up to 5 of which may be established patients, during a period of not less than 18 months for each patient, to ophthalmologists according to the following criteria: </span></p><p class="csF0A1D375" style="tab-stops:left 18pt left 36pt left 54pt left 72pt left 90pt;"><span class="csDD5E5F52">\t\t\t\t(1) &nbsp;A new or existing glaucoma patient is examined and diagnosed by the optometrist; </span></p><p class="csF0A1D375" style="tab-stops:left 18pt left 36pt left 54pt left 72pt left 90pt;"><span class="csDD5E5F52">\t\t\t\t(2) &nbsp;The optometrist develops a proposed treatment plan and forwards the plan with examination documentation to an ophthalmologist for consultation; </span></p><p class="csF0A1D375" style="tab-stops:left 18pt left 36pt left 54pt left 72pt left 90pt;"><span class="csDD5E5F52">\t\t\t\t(3) &nbsp;The ophthalmologist [</span><span class="cs98AF35F2">examines the patient and</span><span class="csDD5E5F52">] reviews the optometrist&#39;s examination documentation and proposed treatment plan; </span></p><p class="csF0A1D375" style="tab-stops:left 18pt left 36pt left 54pt left 72pt left 90pt;"><span class="csDD5E5F52">\t\t\t\t(4) &nbsp;The ophthalmologist, optometrist, and patient mutually agree to and document a treatment plan; </span></p><p class="csF0A1D375" style="tab-stops:left 18pt left 36pt left 54pt left 72pt left 90pt;"><span class="csDD5E5F52">\t\t\t\t(5) &nbsp;The optometrist shall consult with the co-managing ophthalmologist when any of the following occurs: the patient&#39;s target pressure is not reached within 90 days; the patient is experiencing documented progression of optic nerve damage; the patient develops documented and repeated progression of visual field loss; or the patient develops angle-closure [</span><span class="cs98AF35F2">or other secondary glaucoma</span><span class="csDD5E5F52">]; and </span></p><p class="csF0A1D375" style="tab-stops:left 18pt left 36pt left 54pt left 72pt left 90pt;"><span class="csDD5E5F52">\t\t\t\t(6) &nbsp;For each successfully co-managed glaucoma patient the optometrist and co-managing ophthalmologist shall complete a glaucoma credentialing reporting form and submit the form to the joint credentialing committee upon completion of the 18 months of treatment. </span></p><p class="csF0A1D375" style="tab-stops:left 18pt left 36pt left 54pt left 72pt left 90pt;"><span class="csDD5E5F52">\t\tIII. &nbsp;The joint credentialing committee may waive or reduce the requirements of RSA 327:6-c, I and II for the following categories of optometrists: </span></p><p class="csF0A1D375" style="tab-stops:left 18pt left 36pt left 54pt left 72pt left 90pt;"><span class="csDD5E5F52">\t\t\t(a) &nbsp;Optometrists with a license and proof of practice for 12 months treating glaucoma patients in another state that currently authorizes the treatment of glaucoma by optometrists; or </span></p><p class="csF0A1D375" style="tab-stops:left 18pt left 36pt left 54pt left 72pt left 90pt;"><span class="csDD5E5F52">\t\t\t(b) &nbsp;Optometrists who have proof of successful completion of a 12-month accredited optometric residency program or its equivalent. </span></p><p class="csF0A1D375" style="tab-stops:left 18pt left 36pt left 54pt left 72pt left 90pt;"><span class="csDD5E5F52">\t\tIV. &nbsp;Upon certification to treat glaucoma patients[</span><span class="cs98AF35F2">: </span></p><p class="csF0A1D375" style="tab-stops:left 18pt left 36pt left 54pt left 72pt left 90pt;"><span class="csDD5E5F52">\t\t\t</span><span class="cs98AF35F2">(a) &nbsp;For a period of 24 months, optometrists shall consult with an ophthalmologist within 30 days for each new glaucoma patient for confirmation of diagnosis and review of treatment plan. </span></p><p class="csF0A1D375" style="tab-stops:left 18pt left 36pt left 54pt left 72pt left 90pt;"><span class="csDD5E5F52">\t\t\t</span><span class="cs98AF35F2">(b)</span><span class="csDD5E5F52">] &nbsp;An optometrist shall consult with an ophthalmologist within 30 days when any of the following occurs: </span></p><p class="csF0A1D375" style="tab-stops:left 18pt left 36pt left 54pt left 72pt left 90pt;"><span class="csDD5E5F52">\t\t\t\t[</span><span class="cs98AF35F2">(1)</span><span class="csDD5E5F52">] </span><span class="cs22FF6315">(a) &nbsp;</span><span class="csDD5E5F52">The patient is experiencing documented progression of optic nerve damage or the patient develops documented and repeated progression of visual field loss on maximum tolerated topical medical therapy; or </span></p><p class="csF0A1D375" style="tab-stops:left 18pt left 36pt left 54pt left 72pt left 90pt;"><span class="csDD5E5F52">\t\t\t\t</span><span class="cs98AF35F2">[(2)</span><span class="csDD5E5F52">] </span><span class="cs22FF6315">(b) &nbsp;</span><span class="csDD5E5F52">The patient develops angle-closure [</span><span class="cs98AF35F2">or other secondary glaucoma</span><span class="csDD5E5F52">]. </span></p><p class="csF0A1D375" style="tab-stops:left 18pt left 36pt left 54pt left 72pt left 90pt;"><span class="csDD5E5F52">\t</span><a name="CHAPT"></a><span class="csDD5E5F52">2 &nbsp;Effective Date. &nbsp;This act shall take effect 60 days after its passage.</span></p>'